# Continuing Efforts to See Cannabis Declassified | Congressman Steve Cohen > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-descheduling-clinical-implications/ > **Published:** 2026-04-25T17:03:10-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:10:41-04:00 > **Clinical Summary:** Explore cannabis descheduling clinical implications and how federal policy reform could transform research and medical practice in cannabis medicine. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyFederal RegulationResearch Access[Clinical Practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/)Scheduling Why This Matters Federal reclassification or descheduling would fundamentally alter the research and clinical landscape for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). Current Schedule I status creates significant barriers to controlled [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and limits physician prescribing options to state-legal recommendations rather than FDA-approved therapeutics. Clinical Summary Congressman Cohen advocates for cannabis descheduling, which would remove it entirely from the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act rather than simply moving it to a lower schedule. This differs from rescheduling proposals that would maintain federal control while reducing restrictions. Descheduling would eliminate federal criminalization and potentially allow for standard pharmaceutical development pathways, though state regulations would still apply. The clinical implications include expanded research opportunities and potential access to standardized, FDA-regulated cannabis medications. Dr. Caplan’s Take “While I support evidence-based policy reform, the clinical reality is that descheduling alone won’t solve our biggest challenge: the lack of high-quality, standardized products with consistent dosing and reliable therapeutic windows that patients desperately need.” Clinical Perspective 🧠 Clinicians should understand that any scheduling change will likely take years to implement and won’t immediately change day-to-day practice. The focus should remain on working within current state frameworks to optimize patient outcomes with available products. Watch for how any federal changes might affect state medical programs, banking access for dispensaries, and research funding opportunities. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Continuing%20My%20Efforts%20to%20See%20Cannabis%20Declassified%20%7C%20Congressman%20Steve%20Cohen%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcontinuing-my-efforts-to-see-cannabis-declassified-congressman-steve-cohen%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcontinuing-my-efforts-to-see-cannabis-declassified-congressman-steve-cohen%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Continuing%20My%20Efforts%20to%20See%20Cannabis%20Declassified%20%7C%20Congressman%20Steve%20Cohen%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcontinuing-my-efforts-to-see-cannabis-declassified-congressman-steve-cohen%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://cohen.house.gov/media-center/enewsletters/continuing-my-efforts-see-cannabis-declassified](https://cohen.house.gov/media-center/enewsletters/continuing-my-efforts-see-cannabis-declassified) Table of Contents - [FAQ](#FAQ)[What type of clinical relevance does this cannabis news have?](#What_type_of_clinical_relevance_does_this_cannabis_news_have) - [What areas does this cannabis policy update cover?](#What_areas_does_this_cannabis_policy_update_cover) - [How might this affect medical cannabis research?](#How_might_this_affect_medical_cannabis_research) - [What should clinicians know about these policy changes?](#What_should_clinicians_know_about_these_policy_changes) - [Why is this considered an emerging development worth monitoring?](#Why_is_this_considered_an_emerging_development_worth_monitoring) - [Related](#Related) ## FAQ #### What type of clinical relevance does this cannabis news have? This article has a Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” It represents emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What areas does this cannabis policy update cover? The update covers multiple key areas including policy changes, federal regulation modifications, research access improvements, and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) implications. These interconnected topics suggest comprehensive changes to cannabis oversight and medical use. #### How might this affect medical cannabis research? The focus on research access suggests potential improvements in how researchers can study cannabis for medical purposes. This could lead to expanded [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and better evidence-based treatment protocols. #### What should clinicians know about these policy changes? Healthcare providers should stay informed about these emerging policy developments as they may impact prescribing practices and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) protocols. The clinical practice implications suggest direct relevance to day-to-day medical decision-making. #### Why is this considered an emerging development worth monitoring? The designation as “emerging findings” with “notable clinical interest” indicates these are recent or developing changes that haven’t fully materialized yet. Healthcare professionals should track these developments as they may significantly impact future [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practices. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DOJ Moves to Loosen Cannabis Restrictions, Signals Shift Toward Rescheduling](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) Learn about the Department of Justice's recent actions that indicate a shift toward cannabis rescheduling and what it means for federal policy. [Read More](https://cedclinic.com/doj-cannabis-policy-changes-shift-toward-rescheduling/) [Feds Ease Cannabis Restrictions—and Open Options for Researchers – KGUN 9](https://cedclinic.com/federal-cannabis-research-policy-changes/) Discover how eased federal restrictions are expanding research opportunities in cannabis medicine and what this means for clinical studies. [Explore Article](https://cedclinic.com/federal-cannabis-research-policy-changes/) [Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) Understand the regulatory changes involved in rescheduling FDA-approved marijuana products from Schedule I to Schedule III. [Learn More](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).